nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PPARG—pancreatic cancer	0.408	0.703	CbGaD
Mesalazine—PTGS2—pancreatic cancer	0.172	0.297	CbGaD
Mesalazine—MPO—superior mesenteric artery—pancreatic cancer	0.0372	0.656	CbGeAlD
Mesalazine—PPARG—Topotecan—Irinotecan—pancreatic cancer	0.00322	1	CbGdCrCtD
Mesalazine—CHUK—digestive system—pancreatic cancer	0.00241	0.0424	CbGeAlD
Mesalazine—ALOX5—islet of Langerhans—pancreatic cancer	0.00226	0.0398	CbGeAlD
Mesalazine—PPARG—islet of Langerhans—pancreatic cancer	0.0017	0.0299	CbGeAlD
Mesalazine—IKBKB—digestive system—pancreatic cancer	0.00164	0.0289	CbGeAlD
Mesalazine—ALOX5—pancreas—pancreatic cancer	0.00159	0.028	CbGeAlD
Mesalazine—ALOX5—digestive system—pancreatic cancer	0.00136	0.0239	CbGeAlD
Mesalazine—MPO—pancreas—pancreatic cancer	0.00134	0.0237	CbGeAlD
Mesalazine—PTGS2—gall bladder—pancreatic cancer	0.00132	0.0233	CbGeAlD
Mesalazine—PPARG—pancreas—pancreatic cancer	0.00119	0.021	CbGeAlD
Mesalazine—MPO—digestive system—pancreatic cancer	0.00115	0.0202	CbGeAlD
Mesalazine—PPARG—digestive system—pancreatic cancer	0.00102	0.018	CbGeAlD
Mesalazine—Olsalazine—PPARG—pancreatic cancer	0.000968	0.328	CrCbGaD
Mesalazine—PTGS2—islet of Langerhans—pancreatic cancer	0.000866	0.0153	CbGeAlD
Mesalazine—PTGS2—pancreas—pancreatic cancer	0.000609	0.0107	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—pancreatic cancer	0.000596	0.202	CrCbGaD
Mesalazine—PTGS1—digestive system—pancreatic cancer	0.000544	0.0096	CbGeAlD
Mesalazine—PTGS2—digestive system—pancreatic cancer	0.00052	0.00917	CbGeAlD
Mesalazine—Olsalazine—PTGS2—pancreatic cancer	0.000409	0.138	CrCbGaD
Mesalazine—Diflunisal—PTGS2—pancreatic cancer	0.000384	0.13	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—pancreatic cancer	0.000384	0.13	CrCbGaD
Mesalazine—Salicylic acid—PTGS2—pancreatic cancer	0.000214	0.0723	CrCbGaD
Mesalazine—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	6.44e-05	0.000293	CcSEcCtD
Mesalazine—Sweating—Epirubicin—pancreatic cancer	6.41e-05	0.000291	CcSEcCtD
Mesalazine—Pollakiuria—Doxorubicin—pancreatic cancer	6.41e-05	0.000291	CcSEcCtD
Mesalazine—Asthenia—Gemcitabine—pancreatic cancer	6.39e-05	0.00029	CcSEcCtD
Mesalazine—Haematuria—Epirubicin—pancreatic cancer	6.37e-05	0.00029	CcSEcCtD
Mesalazine—Confusional state—Docetaxel—pancreatic cancer	6.37e-05	0.00029	CcSEcCtD
Mesalazine—Photosensitivity reaction—Doxorubicin—pancreatic cancer	6.33e-05	0.000288	CcSEcCtD
Mesalazine—Hepatobiliary disease—Epirubicin—pancreatic cancer	6.32e-05	0.000287	CcSEcCtD
Mesalazine—Oedema—Docetaxel—pancreatic cancer	6.32e-05	0.000287	CcSEcCtD
Mesalazine—Anaphylactic shock—Docetaxel—pancreatic cancer	6.32e-05	0.000287	CcSEcCtD
Mesalazine—Weight increased—Doxorubicin—pancreatic cancer	6.31e-05	0.000287	CcSEcCtD
Mesalazine—Epistaxis—Epirubicin—pancreatic cancer	6.3e-05	0.000287	CcSEcCtD
Mesalazine—Pruritus—Gemcitabine—pancreatic cancer	6.3e-05	0.000286	CcSEcCtD
Mesalazine—Infection—Docetaxel—pancreatic cancer	6.28e-05	0.000285	CcSEcCtD
Mesalazine—Weight decreased—Doxorubicin—pancreatic cancer	6.27e-05	0.000285	CcSEcCtD
Mesalazine—Sinusitis—Epirubicin—pancreatic cancer	6.27e-05	0.000285	CcSEcCtD
Mesalazine—Diarrhoea—Irinotecan—pancreatic cancer	6.25e-05	0.000284	CcSEcCtD
Mesalazine—Agranulocytosis—Epirubicin—pancreatic cancer	6.24e-05	0.000283	CcSEcCtD
Mesalazine—Pneumonia—Doxorubicin—pancreatic cancer	6.22e-05	0.000283	CcSEcCtD
Mesalazine—Shock—Docetaxel—pancreatic cancer	6.22e-05	0.000283	CcSEcCtD
Mesalazine—Nervous system disorder—Docetaxel—pancreatic cancer	6.2e-05	0.000282	CcSEcCtD
Mesalazine—Pruritus—Fluorouracil—pancreatic cancer	6.19e-05	0.000282	CcSEcCtD
Mesalazine—Thrombocytopenia—Docetaxel—pancreatic cancer	6.19e-05	0.000281	CcSEcCtD
Mesalazine—Infestation—Doxorubicin—pancreatic cancer	6.18e-05	0.000281	CcSEcCtD
Mesalazine—Infestation NOS—Doxorubicin—pancreatic cancer	6.18e-05	0.000281	CcSEcCtD
Mesalazine—Tachycardia—Docetaxel—pancreatic cancer	6.17e-05	0.00028	CcSEcCtD
Mesalazine—Skin disorder—Docetaxel—pancreatic cancer	6.14e-05	0.000279	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	6.13e-05	0.000279	CcSEcCtD
Mesalazine—Diarrhoea—Gemcitabine—pancreatic cancer	6.09e-05	0.000277	CcSEcCtD
Mesalazine—Renal failure—Doxorubicin—pancreatic cancer	6.08e-05	0.000276	CcSEcCtD
Mesalazine—Neuropathy peripheral—Doxorubicin—pancreatic cancer	6.06e-05	0.000276	CcSEcCtD
Mesalazine—Dizziness—Irinotecan—pancreatic cancer	6.04e-05	0.000275	CcSEcCtD
Mesalazine—Haemoglobin—Epirubicin—pancreatic cancer	6.03e-05	0.000274	CcSEcCtD
Mesalazine—Stomatitis—Doxorubicin—pancreatic cancer	6.03e-05	0.000274	CcSEcCtD
Mesalazine—Jaundice—Doxorubicin—pancreatic cancer	6.03e-05	0.000274	CcSEcCtD
Mesalazine—Anorexia—Docetaxel—pancreatic cancer	6.02e-05	0.000274	CcSEcCtD
Mesalazine—Rhinitis—Epirubicin—pancreatic cancer	6.01e-05	0.000273	CcSEcCtD
Mesalazine—Conjunctivitis—Doxorubicin—pancreatic cancer	6.01e-05	0.000273	CcSEcCtD
Mesalazine—Urinary tract infection—Doxorubicin—pancreatic cancer	6.01e-05	0.000273	CcSEcCtD
Mesalazine—Hepatitis—Epirubicin—pancreatic cancer	6e-05	0.000273	CcSEcCtD
Mesalazine—Haemorrhage—Epirubicin—pancreatic cancer	6e-05	0.000273	CcSEcCtD
Mesalazine—Diarrhoea—Fluorouracil—pancreatic cancer	5.99e-05	0.000272	CcSEcCtD
Mesalazine—Pharyngitis—Epirubicin—pancreatic cancer	5.95e-05	0.000271	CcSEcCtD
Mesalazine—Sweating—Doxorubicin—pancreatic cancer	5.93e-05	0.000269	CcSEcCtD
Mesalazine—Urinary tract disorder—Epirubicin—pancreatic cancer	5.92e-05	0.000269	CcSEcCtD
Mesalazine—Oedema peripheral—Epirubicin—pancreatic cancer	5.91e-05	0.000269	CcSEcCtD
Mesalazine—Hypotension—Docetaxel—pancreatic cancer	5.9e-05	0.000268	CcSEcCtD
Mesalazine—Haematuria—Doxorubicin—pancreatic cancer	5.9e-05	0.000268	CcSEcCtD
Mesalazine—Connective tissue disorder—Epirubicin—pancreatic cancer	5.89e-05	0.000268	CcSEcCtD
Mesalazine—Urethral disorder—Epirubicin—pancreatic cancer	5.88e-05	0.000267	CcSEcCtD
Mesalazine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	5.85e-05	0.000266	CcSEcCtD
Mesalazine—Epistaxis—Doxorubicin—pancreatic cancer	5.83e-05	0.000265	CcSEcCtD
Mesalazine—Vomiting—Irinotecan—pancreatic cancer	5.81e-05	0.000264	CcSEcCtD
Mesalazine—Sinusitis—Doxorubicin—pancreatic cancer	5.8e-05	0.000264	CcSEcCtD
Mesalazine—Dizziness—Fluorouracil—pancreatic cancer	5.79e-05	0.000263	CcSEcCtD
Mesalazine—Agranulocytosis—Doxorubicin—pancreatic cancer	5.77e-05	0.000262	CcSEcCtD
Mesalazine—Rash—Irinotecan—pancreatic cancer	5.76e-05	0.000262	CcSEcCtD
Mesalazine—Dermatitis—Irinotecan—pancreatic cancer	5.76e-05	0.000262	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	5.76e-05	0.000262	CcSEcCtD
Mesalazine—Headache—Irinotecan—pancreatic cancer	5.73e-05	0.00026	CcSEcCtD
Mesalazine—Insomnia—Docetaxel—pancreatic cancer	5.71e-05	0.00026	CcSEcCtD
Mesalazine—Paraesthesia—Docetaxel—pancreatic cancer	5.67e-05	0.000258	CcSEcCtD
Mesalazine—Erythema multiforme—Epirubicin—pancreatic cancer	5.67e-05	0.000258	CcSEcCtD
Mesalazine—Vomiting—Gemcitabine—pancreatic cancer	5.66e-05	0.000257	CcSEcCtD
Mesalazine—Dyspnoea—Docetaxel—pancreatic cancer	5.63e-05	0.000256	CcSEcCtD
Mesalazine—Somnolence—Docetaxel—pancreatic cancer	5.62e-05	0.000255	CcSEcCtD
Mesalazine—Rash—Gemcitabine—pancreatic cancer	5.61e-05	0.000255	CcSEcCtD
Mesalazine—Dermatitis—Gemcitabine—pancreatic cancer	5.61e-05	0.000255	CcSEcCtD
Mesalazine—Eye disorder—Epirubicin—pancreatic cancer	5.61e-05	0.000255	CcSEcCtD
Mesalazine—Tinnitus—Epirubicin—pancreatic cancer	5.59e-05	0.000254	CcSEcCtD
Mesalazine—Haemoglobin—Doxorubicin—pancreatic cancer	5.58e-05	0.000254	CcSEcCtD
Mesalazine—Headache—Gemcitabine—pancreatic cancer	5.58e-05	0.000254	CcSEcCtD
Mesalazine—Cardiac disorder—Epirubicin—pancreatic cancer	5.57e-05	0.000253	CcSEcCtD
Mesalazine—Vomiting—Fluorouracil—pancreatic cancer	5.57e-05	0.000253	CcSEcCtD
Mesalazine—Rhinitis—Doxorubicin—pancreatic cancer	5.56e-05	0.000253	CcSEcCtD
Mesalazine—Dyspepsia—Docetaxel—pancreatic cancer	5.56e-05	0.000253	CcSEcCtD
Mesalazine—Haemorrhage—Doxorubicin—pancreatic cancer	5.55e-05	0.000252	CcSEcCtD
Mesalazine—Hepatitis—Doxorubicin—pancreatic cancer	5.55e-05	0.000252	CcSEcCtD
Mesalazine—Rash—Fluorouracil—pancreatic cancer	5.52e-05	0.000251	CcSEcCtD
Mesalazine—Dermatitis—Fluorouracil—pancreatic cancer	5.51e-05	0.000251	CcSEcCtD
Mesalazine—Pharyngitis—Doxorubicin—pancreatic cancer	5.51e-05	0.00025	CcSEcCtD
Mesalazine—Decreased appetite—Docetaxel—pancreatic cancer	5.49e-05	0.00025	CcSEcCtD
Mesalazine—Headache—Fluorouracil—pancreatic cancer	5.48e-05	0.000249	CcSEcCtD
Mesalazine—Urinary tract disorder—Doxorubicin—pancreatic cancer	5.48e-05	0.000249	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—pancreatic cancer	5.47e-05	0.000249	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	5.45e-05	0.000248	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—pancreatic cancer	5.45e-05	0.000248	CcSEcCtD
Mesalazine—Fatigue—Docetaxel—pancreatic cancer	5.45e-05	0.000248	CcSEcCtD
Mesalazine—Angiopathy—Epirubicin—pancreatic cancer	5.44e-05	0.000247	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—pancreatic cancer	5.44e-05	0.000247	CcSEcCtD
Mesalazine—Nausea—Irinotecan—pancreatic cancer	5.43e-05	0.000247	CcSEcCtD
Mesalazine—Immune system disorder—Epirubicin—pancreatic cancer	5.42e-05	0.000246	CcSEcCtD
Mesalazine—Mediastinal disorder—Epirubicin—pancreatic cancer	5.41e-05	0.000246	CcSEcCtD
Mesalazine—Pain—Docetaxel—pancreatic cancer	5.4e-05	0.000246	CcSEcCtD
Mesalazine—Constipation—Docetaxel—pancreatic cancer	5.4e-05	0.000246	CcSEcCtD
Mesalazine—Chills—Epirubicin—pancreatic cancer	5.38e-05	0.000245	CcSEcCtD
Mesalazine—Alopecia—Epirubicin—pancreatic cancer	5.3e-05	0.000241	CcSEcCtD
Mesalazine—Nausea—Gemcitabine—pancreatic cancer	5.29e-05	0.00024	CcSEcCtD
Mesalazine—Mental disorder—Epirubicin—pancreatic cancer	5.26e-05	0.000239	CcSEcCtD
Mesalazine—Erythema multiforme—Doxorubicin—pancreatic cancer	5.25e-05	0.000239	CcSEcCtD
Mesalazine—Erythema—Epirubicin—pancreatic cancer	5.22e-05	0.000237	CcSEcCtD
Mesalazine—Feeling abnormal—Docetaxel—pancreatic cancer	5.21e-05	0.000237	CcSEcCtD
Mesalazine—Nausea—Fluorouracil—pancreatic cancer	5.2e-05	0.000236	CcSEcCtD
Mesalazine—Eye disorder—Doxorubicin—pancreatic cancer	5.19e-05	0.000236	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—pancreatic cancer	5.18e-05	0.000235	CcSEcCtD
Mesalazine—Gastrointestinal pain—Docetaxel—pancreatic cancer	5.17e-05	0.000235	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—pancreatic cancer	5.15e-05	0.000234	CcSEcCtD
Mesalazine—Flatulence—Epirubicin—pancreatic cancer	5.15e-05	0.000234	CcSEcCtD
Mesalazine—Tension—Epirubicin—pancreatic cancer	5.12e-05	0.000233	CcSEcCtD
Mesalazine—Dysgeusia—Epirubicin—pancreatic cancer	5.11e-05	0.000232	CcSEcCtD
Mesalazine—Nervousness—Epirubicin—pancreatic cancer	5.07e-05	0.000231	CcSEcCtD
Mesalazine—Back pain—Epirubicin—pancreatic cancer	5.05e-05	0.00023	CcSEcCtD
Mesalazine—Angiopathy—Doxorubicin—pancreatic cancer	5.04e-05	0.000229	CcSEcCtD
Mesalazine—Muscle spasms—Epirubicin—pancreatic cancer	5.02e-05	0.000228	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—pancreatic cancer	5.01e-05	0.000228	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—pancreatic cancer	5e-05	0.000227	CcSEcCtD
Mesalazine—Abdominal pain—Docetaxel—pancreatic cancer	4.99e-05	0.000227	CcSEcCtD
Mesalazine—Body temperature increased—Docetaxel—pancreatic cancer	4.99e-05	0.000227	CcSEcCtD
Mesalazine—Chills—Doxorubicin—pancreatic cancer	4.98e-05	0.000226	CcSEcCtD
Mesalazine—Vision blurred—Epirubicin—pancreatic cancer	4.92e-05	0.000224	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—pancreatic cancer	4.9e-05	0.000223	CcSEcCtD
Mesalazine—Mental disorder—Doxorubicin—pancreatic cancer	4.86e-05	0.000221	CcSEcCtD
Mesalazine—Ill-defined disorder—Epirubicin—pancreatic cancer	4.85e-05	0.00022	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—pancreatic cancer	4.83e-05	0.00022	CcSEcCtD
Mesalazine—Anaemia—Epirubicin—pancreatic cancer	4.83e-05	0.000219	CcSEcCtD
Mesalazine—Flatulence—Doxorubicin—pancreatic cancer	4.76e-05	0.000216	CcSEcCtD
Mesalazine—Tension—Doxorubicin—pancreatic cancer	4.74e-05	0.000216	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—pancreatic cancer	4.73e-05	0.000215	CcSEcCtD
Mesalazine—Malaise—Epirubicin—pancreatic cancer	4.71e-05	0.000214	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—pancreatic cancer	4.69e-05	0.000213	CcSEcCtD
Mesalazine—Vertigo—Epirubicin—pancreatic cancer	4.69e-05	0.000213	CcSEcCtD
Mesalazine—Syncope—Epirubicin—pancreatic cancer	4.68e-05	0.000213	CcSEcCtD
Mesalazine—Leukopenia—Epirubicin—pancreatic cancer	4.67e-05	0.000213	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—pancreatic cancer	4.67e-05	0.000212	CcSEcCtD
Mesalazine—Hypersensitivity—Docetaxel—pancreatic cancer	4.66e-05	0.000212	CcSEcCtD
Mesalazine—Muscle spasms—Doxorubicin—pancreatic cancer	4.65e-05	0.000211	CcSEcCtD
Mesalazine—Palpitations—Epirubicin—pancreatic cancer	4.61e-05	0.00021	CcSEcCtD
Mesalazine—Loss of consciousness—Epirubicin—pancreatic cancer	4.59e-05	0.000209	CcSEcCtD
Mesalazine—Cough—Epirubicin—pancreatic cancer	4.56e-05	0.000207	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—pancreatic cancer	4.55e-05	0.000207	CcSEcCtD
Mesalazine—Asthenia—Docetaxel—pancreatic cancer	4.53e-05	0.000206	CcSEcCtD
Mesalazine—Hypertension—Epirubicin—pancreatic cancer	4.51e-05	0.000205	CcSEcCtD
Mesalazine—Ill-defined disorder—Doxorubicin—pancreatic cancer	4.48e-05	0.000204	CcSEcCtD
Mesalazine—Pruritus—Docetaxel—pancreatic cancer	4.47e-05	0.000203	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—pancreatic cancer	4.47e-05	0.000203	CcSEcCtD
Mesalazine—Arthralgia—Epirubicin—pancreatic cancer	4.45e-05	0.000202	CcSEcCtD
Mesalazine—Chest pain—Epirubicin—pancreatic cancer	4.45e-05	0.000202	CcSEcCtD
Mesalazine—Myalgia—Epirubicin—pancreatic cancer	4.45e-05	0.000202	CcSEcCtD
Mesalazine—Anxiety—Epirubicin—pancreatic cancer	4.43e-05	0.000201	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	4.42e-05	0.000201	CcSEcCtD
Mesalazine—Discomfort—Epirubicin—pancreatic cancer	4.39e-05	0.0002	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—pancreatic cancer	4.36e-05	0.000198	CcSEcCtD
Mesalazine—Dry mouth—Epirubicin—pancreatic cancer	4.35e-05	0.000198	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—pancreatic cancer	4.34e-05	0.000197	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—pancreatic cancer	4.33e-05	0.000197	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—pancreatic cancer	4.32e-05	0.000197	CcSEcCtD
Mesalazine—Diarrhoea—Docetaxel—pancreatic cancer	4.32e-05	0.000197	CcSEcCtD
Mesalazine—Confusional state—Epirubicin—pancreatic cancer	4.3e-05	0.000195	CcSEcCtD
Mesalazine—Palpitations—Doxorubicin—pancreatic cancer	4.27e-05	0.000194	CcSEcCtD
Mesalazine—Anaphylactic shock—Epirubicin—pancreatic cancer	4.26e-05	0.000194	CcSEcCtD
Mesalazine—Oedema—Epirubicin—pancreatic cancer	4.26e-05	0.000194	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—pancreatic cancer	4.25e-05	0.000193	CcSEcCtD
Mesalazine—Infection—Epirubicin—pancreatic cancer	4.23e-05	0.000192	CcSEcCtD
Mesalazine—Cough—Doxorubicin—pancreatic cancer	4.22e-05	0.000192	CcSEcCtD
Mesalazine—Shock—Epirubicin—pancreatic cancer	4.19e-05	0.000191	CcSEcCtD
Mesalazine—Nervous system disorder—Epirubicin—pancreatic cancer	4.18e-05	0.00019	CcSEcCtD
Mesalazine—Dizziness—Docetaxel—pancreatic cancer	4.18e-05	0.00019	CcSEcCtD
Mesalazine—Thrombocytopenia—Epirubicin—pancreatic cancer	4.17e-05	0.00019	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—pancreatic cancer	4.17e-05	0.00019	CcSEcCtD
Mesalazine—Tachycardia—Epirubicin—pancreatic cancer	4.16e-05	0.000189	CcSEcCtD
Mesalazine—Skin disorder—Epirubicin—pancreatic cancer	4.14e-05	0.000188	CcSEcCtD
Mesalazine—Hyperhidrosis—Epirubicin—pancreatic cancer	4.12e-05	0.000187	CcSEcCtD
Mesalazine—Myalgia—Doxorubicin—pancreatic cancer	4.11e-05	0.000187	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—pancreatic cancer	4.11e-05	0.000187	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—pancreatic cancer	4.11e-05	0.000187	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—pancreatic cancer	4.1e-05	0.000186	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	4.09e-05	0.000186	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—pancreatic cancer	4.06e-05	0.000185	CcSEcCtD
Mesalazine—Anorexia—Epirubicin—pancreatic cancer	4.06e-05	0.000185	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—pancreatic cancer	4.02e-05	0.000183	CcSEcCtD
Mesalazine—Vomiting—Docetaxel—pancreatic cancer	4.02e-05	0.000183	CcSEcCtD
Mesalazine—Rash—Docetaxel—pancreatic cancer	3.98e-05	0.000181	CcSEcCtD
Mesalazine—Hypotension—Epirubicin—pancreatic cancer	3.98e-05	0.000181	CcSEcCtD
Mesalazine—Dermatitis—Docetaxel—pancreatic cancer	3.98e-05	0.000181	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—pancreatic cancer	3.98e-05	0.000181	CcSEcCtD
Mesalazine—Headache—Docetaxel—pancreatic cancer	3.96e-05	0.00018	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—pancreatic cancer	3.94e-05	0.000179	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—pancreatic cancer	3.94e-05	0.000179	CcSEcCtD
Mesalazine—Infection—Doxorubicin—pancreatic cancer	3.92e-05	0.000178	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	3.88e-05	0.000177	CcSEcCtD
Mesalazine—Shock—Doxorubicin—pancreatic cancer	3.88e-05	0.000176	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—pancreatic cancer	3.87e-05	0.000176	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—pancreatic cancer	3.86e-05	0.000176	CcSEcCtD
Mesalazine—Insomnia—Epirubicin—pancreatic cancer	3.85e-05	0.000175	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—pancreatic cancer	3.85e-05	0.000175	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—pancreatic cancer	3.83e-05	0.000174	CcSEcCtD
Mesalazine—Paraesthesia—Epirubicin—pancreatic cancer	3.83e-05	0.000174	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—pancreatic cancer	3.81e-05	0.000173	CcSEcCtD
Mesalazine—Dyspnoea—Epirubicin—pancreatic cancer	3.8e-05	0.000173	CcSEcCtD
Mesalazine—Somnolence—Epirubicin—pancreatic cancer	3.79e-05	0.000172	CcSEcCtD
Mesalazine—Anorexia—Doxorubicin—pancreatic cancer	3.76e-05	0.000171	CcSEcCtD
Mesalazine—Nausea—Docetaxel—pancreatic cancer	3.75e-05	0.000171	CcSEcCtD
Mesalazine—Dyspepsia—Epirubicin—pancreatic cancer	3.75e-05	0.000171	CcSEcCtD
Mesalazine—Decreased appetite—Epirubicin—pancreatic cancer	3.7e-05	0.000168	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—pancreatic cancer	3.68e-05	0.000168	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.68e-05	0.000167	CcSEcCtD
Mesalazine—Fatigue—Epirubicin—pancreatic cancer	3.67e-05	0.000167	CcSEcCtD
Mesalazine—Pain—Epirubicin—pancreatic cancer	3.64e-05	0.000166	CcSEcCtD
Mesalazine—Constipation—Epirubicin—pancreatic cancer	3.64e-05	0.000166	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.59e-05	0.000163	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—pancreatic cancer	3.57e-05	0.000162	CcSEcCtD
Mesalazine—Paraesthesia—Doxorubicin—pancreatic cancer	3.54e-05	0.000161	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—pancreatic cancer	3.52e-05	0.00016	CcSEcCtD
Mesalazine—Feeling abnormal—Epirubicin—pancreatic cancer	3.51e-05	0.00016	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—pancreatic cancer	3.51e-05	0.000159	CcSEcCtD
Mesalazine—Gastrointestinal pain—Epirubicin—pancreatic cancer	3.48e-05	0.000158	CcSEcCtD
Mesalazine—Dyspepsia—Doxorubicin—pancreatic cancer	3.47e-05	0.000158	CcSEcCtD
Mesalazine—Decreased appetite—Doxorubicin—pancreatic cancer	3.43e-05	0.000156	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.4e-05	0.000155	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—pancreatic cancer	3.4e-05	0.000155	CcSEcCtD
Mesalazine—Urticaria—Epirubicin—pancreatic cancer	3.39e-05	0.000154	CcSEcCtD
Mesalazine—Pain—Doxorubicin—pancreatic cancer	3.37e-05	0.000153	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—pancreatic cancer	3.37e-05	0.000153	CcSEcCtD
Mesalazine—Abdominal pain—Epirubicin—pancreatic cancer	3.37e-05	0.000153	CcSEcCtD
Mesalazine—Body temperature increased—Epirubicin—pancreatic cancer	3.37e-05	0.000153	CcSEcCtD
Mesalazine—Feeling abnormal—Doxorubicin—pancreatic cancer	3.25e-05	0.000148	CcSEcCtD
Mesalazine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	3.22e-05	0.000147	CcSEcCtD
Mesalazine—Hypersensitivity—Epirubicin—pancreatic cancer	3.14e-05	0.000143	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—pancreatic cancer	3.13e-05	0.000142	CcSEcCtD
Mesalazine—Body temperature increased—Doxorubicin—pancreatic cancer	3.12e-05	0.000142	CcSEcCtD
Mesalazine—Abdominal pain—Doxorubicin—pancreatic cancer	3.12e-05	0.000142	CcSEcCtD
Mesalazine—Asthenia—Epirubicin—pancreatic cancer	3.06e-05	0.000139	CcSEcCtD
Mesalazine—Pruritus—Epirubicin—pancreatic cancer	3.02e-05	0.000137	CcSEcCtD
Mesalazine—Diarrhoea—Epirubicin—pancreatic cancer	2.92e-05	0.000133	CcSEcCtD
Mesalazine—Hypersensitivity—Doxorubicin—pancreatic cancer	2.91e-05	0.000132	CcSEcCtD
Mesalazine—Asthenia—Doxorubicin—pancreatic cancer	2.83e-05	0.000129	CcSEcCtD
Mesalazine—Dizziness—Epirubicin—pancreatic cancer	2.82e-05	0.000128	CcSEcCtD
Mesalazine—Pruritus—Doxorubicin—pancreatic cancer	2.79e-05	0.000127	CcSEcCtD
Mesalazine—Vomiting—Epirubicin—pancreatic cancer	2.71e-05	0.000123	CcSEcCtD
Mesalazine—Diarrhoea—Doxorubicin—pancreatic cancer	2.7e-05	0.000123	CcSEcCtD
Mesalazine—Rash—Epirubicin—pancreatic cancer	2.69e-05	0.000122	CcSEcCtD
Mesalazine—Dermatitis—Epirubicin—pancreatic cancer	2.68e-05	0.000122	CcSEcCtD
Mesalazine—Headache—Epirubicin—pancreatic cancer	2.67e-05	0.000121	CcSEcCtD
Mesalazine—Dizziness—Doxorubicin—pancreatic cancer	2.61e-05	0.000119	CcSEcCtD
Mesalazine—Nausea—Epirubicin—pancreatic cancer	2.53e-05	0.000115	CcSEcCtD
Mesalazine—Vomiting—Doxorubicin—pancreatic cancer	2.51e-05	0.000114	CcSEcCtD
Mesalazine—Rash—Doxorubicin—pancreatic cancer	2.49e-05	0.000113	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—pancreatic cancer	2.48e-05	0.000113	CcSEcCtD
Mesalazine—Headache—Doxorubicin—pancreatic cancer	2.47e-05	0.000112	CcSEcCtD
Mesalazine—Nausea—Doxorubicin—pancreatic cancer	2.34e-05	0.000106	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—TGFB1—pancreatic cancer	1.76e-05	0.000129	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TSC2—pancreatic cancer	1.76e-05	0.000129	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HSPA1B—pancreatic cancer	1.75e-05	0.000129	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CNR1—pancreatic cancer	1.75e-05	0.000128	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—TYMS—pancreatic cancer	1.74e-05	0.000128	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—EGFR—pancreatic cancer	1.73e-05	0.000127	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GLP1R—pancreatic cancer	1.73e-05	0.000127	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	1.73e-05	0.000127	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SST—pancreatic cancer	1.72e-05	0.000126	CbGpPWpGaD
Mesalazine—CHUK—Disease—TERT—pancreatic cancer	1.7e-05	0.000125	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—DPYD—pancreatic cancer	1.7e-05	0.000125	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PTEN—pancreatic cancer	1.69e-05	0.000124	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GCG—pancreatic cancer	1.69e-05	0.000124	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—JAG1—pancreatic cancer	1.68e-05	0.000123	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—NOTCH1—pancreatic cancer	1.68e-05	0.000123	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOTCH3—pancreatic cancer	1.67e-05	0.000123	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TNF—pancreatic cancer	1.65e-05	0.000121	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CTNNB1—pancreatic cancer	1.64e-05	0.00012	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—SRC—pancreatic cancer	1.63e-05	0.00012	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—KRAS—pancreatic cancer	1.63e-05	0.00012	CbGpPWpGaD
Mesalazine—CHUK—Disease—HIF1A—pancreatic cancer	1.62e-05	0.000119	CbGpPWpGaD
Mesalazine—CHUK—Disease—TSC2—pancreatic cancer	1.62e-05	0.000119	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—AKT1—pancreatic cancer	1.61e-05	0.000119	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC2A2—pancreatic cancer	1.61e-05	0.000118	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AGTR1—pancreatic cancer	1.61e-05	0.000118	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—BCL2L1—pancreatic cancer	1.6e-05	0.000118	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NFKBIA—pancreatic cancer	1.6e-05	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PTEN—pancreatic cancer	1.6e-05	0.000117	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.59e-05	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TSC2—pancreatic cancer	1.59e-05	0.000117	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STK11—pancreatic cancer	1.59e-05	0.000117	CbGpPWpGaD
Mesalazine—CHUK—Disease—APOE—pancreatic cancer	1.59e-05	0.000116	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CNR1—pancreatic cancer	1.59e-05	0.000116	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CB—pancreatic cancer	1.58e-05	0.000116	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—NRAS—pancreatic cancer	1.57e-05	0.000115	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CD44—pancreatic cancer	1.57e-05	0.000115	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—SRC—pancreatic cancer	1.57e-05	0.000115	CbGpPWpGaD
Mesalazine—PTGS2—Disease—JAG1—pancreatic cancer	1.57e-05	0.000115	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—pancreatic cancer	1.57e-05	0.000115	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.54e-05	0.000113	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.54e-05	0.000113	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PTEN—pancreatic cancer	1.53e-05	0.000113	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGF—pancreatic cancer	1.53e-05	0.000112	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GCG—pancreatic cancer	1.53e-05	0.000112	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.52e-05	0.000112	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—NRAS—pancreatic cancer	1.51e-05	0.000111	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GCG—pancreatic cancer	1.51e-05	0.000111	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD44—pancreatic cancer	1.49e-05	0.000109	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—SRC—pancreatic cancer	1.48e-05	0.000109	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HSPA1A—pancreatic cancer	1.48e-05	0.000109	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOTCH1—pancreatic cancer	1.46e-05	0.000107	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AGTR1—pancreatic cancer	1.46e-05	0.000107	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	1.46e-05	0.000107	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NFKBIA—pancreatic cancer	1.45e-05	0.000107	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STK11—pancreatic cancer	1.44e-05	0.000106	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EGFR—pancreatic cancer	1.43e-05	0.000105	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDH1—pancreatic cancer	1.43e-05	0.000105	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—NRAS—pancreatic cancer	1.43e-05	0.000105	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—SRC—pancreatic cancer	1.42e-05	0.000104	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—STK11—pancreatic cancer	1.42e-05	0.000104	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGF—pancreatic cancer	1.41e-05	0.000104	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—APOE—pancreatic cancer	1.41e-05	0.000104	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.4e-05	0.000103	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SMAD4—pancreatic cancer	1.39e-05	0.000102	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGF—pancreatic cancer	1.39e-05	0.000102	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—HRAS—pancreatic cancer	1.39e-05	0.000102	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—EGFR—pancreatic cancer	1.38e-05	0.000101	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—NRAS—pancreatic cancer	1.37e-05	0.0001	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTEN—pancreatic cancer	1.37e-05	0.0001	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CD—pancreatic cancer	1.36e-05	0.0001	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HES1—pancreatic cancer	1.36e-05	9.96e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—KRAS—pancreatic cancer	1.35e-05	9.93e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.34e-05	9.83e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.33e-05	9.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KRAS—pancreatic cancer	1.3e-05	9.54e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EGFR—pancreatic cancer	1.3e-05	9.53e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDH1—pancreatic cancer	1.29e-05	9.49e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CG—pancreatic cancer	1.28e-05	9.37e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SMAD4—pancreatic cancer	1.26e-05	9.25e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CD—pancreatic cancer	1.26e-05	9.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CD44—pancreatic cancer	1.25e-05	9.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—EGFR—pancreatic cancer	1.25e-05	9.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PIK3CA—pancreatic cancer	1.24e-05	9.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CD—pancreatic cancer	1.24e-05	9.07e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HES1—pancreatic cancer	1.23e-05	9.03e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—KRAS—pancreatic cancer	1.23e-05	9.01e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—AKT1—pancreatic cancer	1.22e-05	8.99e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.22e-05	8.97e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—TYMS—pancreatic cancer	1.22e-05	8.94e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GCG—pancreatic cancer	1.2e-05	8.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PIK3CA—pancreatic cancer	1.19e-05	8.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TERT—pancreatic cancer	1.19e-05	8.73e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CB—pancreatic cancer	1.19e-05	8.72e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—pancreatic cancer	1.18e-05	8.65e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SMAD4—pancreatic cancer	1.18e-05	8.63e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—pancreatic cancer	1.15e-05	8.44e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HES1—pancreatic cancer	1.15e-05	8.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HIF1A—pancreatic cancer	1.14e-05	8.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TSC2—pancreatic cancer	1.13e-05	8.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PIK3CA—pancreatic cancer	1.13e-05	8.27e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—STK11—pancreatic cancer	1.12e-05	8.25e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CD—pancreatic cancer	1.12e-05	8.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOE—pancreatic cancer	1.11e-05	8.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—pancreatic cancer	1.1e-05	8.11e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CB—pancreatic cancer	1.1e-05	8.05e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KDR—pancreatic cancer	1.09e-05	7.99e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—pancreatic cancer	1.09e-05	7.98e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—pancreatic cancer	1.08e-05	7.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TERT—pancreatic cancer	1.08e-05	7.92e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CB—pancreatic cancer	1.08e-05	7.91e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.06e-05	7.75e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CTNNB1—pancreatic cancer	1.05e-05	7.73e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—pancreatic cancer	1.04e-05	7.66e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NFKBIA—pancreatic cancer	1.03e-05	7.6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HIF1A—pancreatic cancer	1.03e-05	7.57e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TSC2—pancreatic cancer	1.03e-05	7.55e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTEN—pancreatic cancer	1.03e-05	7.53e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOTCH1—pancreatic cancer	1.02e-05	7.52e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—pancreatic cancer	1.02e-05	7.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOE—pancreatic cancer	1.01e-05	7.39e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TERT—pancreatic cancer	1.01e-05	7.39e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CG—pancreatic cancer	1e-05	7.36e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—pancreatic cancer	1e-05	7.35e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOE—pancreatic cancer	9.91e-06	7.27e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGF—pancreatic cancer	9.91e-06	7.27e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KDR—pancreatic cancer	9.86e-06	7.24e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CB—pancreatic cancer	9.78e-06	7.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—pancreatic cancer	9.75e-06	7.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CTNNB1—pancreatic cancer	9.72e-06	7.14e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—pancreatic cancer	9.69e-06	7.11e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TYMS—pancreatic cancer	9.67e-06	7.1e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—pancreatic cancer	9.63e-06	7.07e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HIF1A—pancreatic cancer	9.62e-06	7.06e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TSC2—pancreatic cancer	9.6e-06	7.05e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CTNNB1—pancreatic cancer	9.55e-06	7.01e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—SRC—pancreatic cancer	9.52e-06	6.99e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTEN—pancreatic cancer	9.48e-06	6.96e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOE—pancreatic cancer	9.39e-06	6.89e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NFKBIA—pancreatic cancer	9.38e-06	6.89e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	9.38e-06	6.89e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTEN—pancreatic cancer	9.31e-06	6.83e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOTCH1—pancreatic cancer	9.29e-06	6.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—pancreatic cancer	9.21e-06	6.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—pancreatic cancer	9.18e-06	6.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRAS—pancreatic cancer	9.16e-06	6.72e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CG—pancreatic cancer	9.09e-06	6.67e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—pancreatic cancer	9.03e-06	6.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGF—pancreatic cancer	8.98e-06	6.59e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CG—pancreatic cancer	8.94e-06	6.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—pancreatic cancer	8.84e-06	6.49e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CD—pancreatic cancer	8.81e-06	6.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—SRC—pancreatic cancer	8.79e-06	6.45e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOTCH1—pancreatic cancer	8.67e-06	6.36e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARG—pancreatic cancer	8.63e-06	6.34e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—SRC—pancreatic cancer	8.63e-06	6.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—pancreatic cancer	8.47e-06	6.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRAS—pancreatic cancer	8.45e-06	6.21e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTEN—pancreatic cancer	8.45e-06	6.2e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGF—pancreatic cancer	8.38e-06	6.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—pancreatic cancer	8.34e-06	6.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—pancreatic cancer	8.32e-06	6.11e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRAS—pancreatic cancer	8.3e-06	6.09e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CD—pancreatic cancer	7.99e-06	5.86e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—pancreatic cancer	7.88e-06	5.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—pancreatic cancer	7.87e-06	5.78e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—pancreatic cancer	7.87e-06	5.78e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOE—pancreatic cancer	7.87e-06	5.77e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CD—pancreatic cancer	7.86e-06	5.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TGFB1—pancreatic cancer	7.86e-06	5.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—pancreatic cancer	7.7e-06	5.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CB—pancreatic cancer	7.68e-06	5.64e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—pancreatic cancer	7.56e-06	5.55e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CD—pancreatic cancer	7.45e-06	5.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.45e-06	5.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL8—pancreatic cancer	7.38e-06	5.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—pancreatic cancer	7.28e-06	5.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—pancreatic cancer	7.24e-06	5.31e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—pancreatic cancer	7.15e-06	5.25e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CG—pancreatic cancer	7.1e-06	5.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CASP3—pancreatic cancer	7.06e-06	5.18e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CB—pancreatic cancer	6.96e-06	5.11e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—pancreatic cancer	6.87e-06	5.05e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CB—pancreatic cancer	6.85e-06	5.03e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARG—pancreatic cancer	6.85e-06	5.03e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CTNNB1—pancreatic cancer	6.81e-06	5e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—pancreatic cancer	6.79e-06	4.98e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—pancreatic cancer	6.7e-06	4.92e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL8—pancreatic cancer	6.69e-06	4.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—pancreatic cancer	6.68e-06	4.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—pancreatic cancer	6.67e-06	4.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTEN—pancreatic cancer	6.64e-06	4.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—pancreatic cancer	6.57e-06	4.82e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CB—pancreatic cancer	6.5e-06	4.77e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CASP3—pancreatic cancer	6.4e-06	4.7e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—pancreatic cancer	6.27e-06	4.6e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CD—pancreatic cancer	6.24e-06	4.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—pancreatic cancer	6.23e-06	4.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—pancreatic cancer	6.18e-06	4.54e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CTNNB1—pancreatic cancer	6.17e-06	4.53e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SRC—pancreatic cancer	6.15e-06	4.52e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—pancreatic cancer	6.07e-06	4.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—pancreatic cancer	6.05e-06	4.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTEN—pancreatic cancer	6.02e-06	4.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—pancreatic cancer	5.99e-06	4.4e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—pancreatic cancer	5.96e-06	4.38e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—pancreatic cancer	5.93e-06	4.36e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTEN—pancreatic cancer	5.92e-06	4.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRAS—pancreatic cancer	5.92e-06	4.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—pancreatic cancer	5.91e-06	4.34e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CTNNB1—pancreatic cancer	5.76e-06	4.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTEN—pancreatic cancer	5.61e-06	4.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SRC—pancreatic cancer	5.58e-06	4.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—pancreatic cancer	5.51e-06	4.05e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFB1—pancreatic cancer	5.5e-06	4.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—pancreatic cancer	5.46e-06	4.01e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CB—pancreatic cancer	5.44e-06	3.99e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—pancreatic cancer	5.43e-06	3.99e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—pancreatic cancer	5.39e-06	3.96e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—pancreatic cancer	5.38e-06	3.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRAS—pancreatic cancer	5.37e-06	3.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—pancreatic cancer	5.36e-06	3.94e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SRC—pancreatic cancer	5.21e-06	3.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—pancreatic cancer	5.1e-06	3.74e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—pancreatic cancer	5.02e-06	3.68e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRAS—pancreatic cancer	5.01e-06	3.68e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—pancreatic cancer	5e-06	3.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFB1—pancreatic cancer	4.99e-06	3.66e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—pancreatic cancer	4.89e-06	3.59e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—pancreatic cancer	4.87e-06	3.58e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTEN—pancreatic cancer	4.7e-06	3.45e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—pancreatic cancer	4.68e-06	3.44e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—pancreatic cancer	4.66e-06	3.42e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFB1—pancreatic cancer	4.65e-06	3.42e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—pancreatic cancer	4.62e-06	3.39e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—pancreatic cancer	4.56e-06	3.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—pancreatic cancer	4.53e-06	3.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—pancreatic cancer	4.33e-06	3.18e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—pancreatic cancer	4.31e-06	3.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—pancreatic cancer	4.24e-06	3.12e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—pancreatic cancer	4.18e-06	3.07e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—pancreatic cancer	4.11e-06	3.01e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—pancreatic cancer	3.96e-06	2.91e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—pancreatic cancer	3.93e-06	2.88e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—pancreatic cancer	3.82e-06	2.81e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—pancreatic cancer	3.66e-06	2.69e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—pancreatic cancer	3.47e-06	2.55e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—pancreatic cancer	3.41e-06	2.5e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—pancreatic cancer	3.32e-06	2.43e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—pancreatic cancer	3.23e-06	2.37e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—pancreatic cancer	2.71e-06	1.99e-05	CbGpPWpGaD
